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Myeloid-derived suppressor cells (MDSC) represent a
heterogeneous population of immature myeloid cells that
accumulate in blood, liver, spleen and tumors upon
chronic inflammation and tumor development in patients
and mice. Acute hepatitis is characterized by a fast infiltra-
tion of inflammatory cells in the liver and increased enzy-
matic activity at this organ that could lead into liver
fibrosis and chirrosis. We have studied the biology of
hepatic MDSC in acute hepatitis. Unexpectedly, hepatic
MDSC, which accumulate in the liver of mice bearing sub-
cutaneous tumors, failed to suppress inflammatory
responses upon Con A injection, but instead were respon-
sible for exacerbating acute liver damage. Phenotypic,
genetic and functional studies demonstrated rapid changes
of hepatic MDSC from a suppressor phenotype into a
pro-inflammatory subset as early as 3 hours after Con A
injection. An increase in the expression of pro-inflamma-
tory cytokines, costimulatory molecules such as CD80,
CD86 and CD40 along with a loss of suppressor function
was noticed in mice upon Con A treatment. These changes
were CD40-dependent and not found in CD40-/- MDSC.
Interestingly, CD40 ligation of human MDSC in vitro
resulted in down-regulation of arginase I expression and
suppressor function. Finally, blockade of ROS production
in hepatic MDSC ameliorated hepatocyte damage suggest-
ing that MDSC mediated toxicity was ROS dependent.
We believe that these findings reflect how MDSC plasticity
can be modulated to promote inflammation, opening a
new path for therapies targeting innate suppressive cells in
cancer patients.
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